Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
Phase: PHASE3
Conditions: COPD Asthma
Sponsor: University of Illinois at Chicago

Page 1 of 13 
 
RESEARCH PROTOCOL 
 
 
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma 
(REDEFINE Study) 
 
 
Version: 1.5 
Date:  1/11/2018 
 
Principal Investigator:  Min Joo MD MPH 
Division of Pulmonary, Critical Care, Sleep, and Allergy, Department of Medicine,  
University of Illinois at Chicago, Chicago, IL  
 
Sponsor: AHRQ 1R01HS024964-01   
 
 
SPECIFIC AIMS AND HYPOTHESIS 
  
Aim 1:  Determine the prevalence of and characteristics associated with diagnostic 
error (DE) in asthma and/or COPD in an underserved population 
Aim 2: Evaluate the effectiveness of the REDEFINE program compared to usual care 
on health care utilization and patient-centered outcomes (including respiratory 
medication use, all-cause emergency room visits, and all-cause hospitlizations) 
Hypothesis: 
The REDEFINE program will reduce health care utilization and improve patien-
centered outcomes compared to  usual care. 
Aim 3: Evaluate the cost impact and cost effectiveness of the REDEFINE program 
versus usual care 
Hypothesis: 
The REDEFINE program will be cost-effective in the management of patients 
with COPD and asthma compared to usual care. 
   
 
BACKGROUND AND SIGNIFICANCE 
 
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic 
lung diseases that are diagnosed in more than 30 million adults in the United States.1,2  
However, diagnostic error (DE), considered one of the most common and harmful of 
patient-safety problems by the Institute of Medicine,3,4 occur frequently with asthma 
and/or COPD and disproportionately affect minorities and the underserved. DE leads to 
lost opportunities to identify other chronic conditions, avoidable morbidity and mortality, 
unnecessary costs to patients and health systems, and poor quality of care.3-6  
Shortness of breath or dyspnea, which is a common symptom in asthma and COPD, is 
also common for many other chronic conditions such as cardiovascular disease and 
obesity.  A better understanding of the impact of DE and interventions to improve 
diagnostic accuracy in asthma and COPD are of particular importance for minorities and 
the underserved that are disproportionately affected by conditions leading to dyspnea. 
 Spirometry is a simple, mobile, and essential test that is recommended by all 
major national and international guidelines for the diagnosis of asthma and COPD. 7-10  

Page 2 of 13 
 
However it is well known that spirometry is not routinely used in the ambulatory primary 
care setting11-19 and minorities and the underserved population are less likely to have 
spirometry leading to greater prevalence of DE.20-25  It has been estimated that 30-50% 
of people with an existing diagnosis of asthma and COPD were found to be 
misdiagnosed.11,20,21,26-32  Many of these patients misdiagnosed with asthma and/or 
COPD receive unnecessary respiratory pharmacotherapy which can pose serious risks 
including pneumonia, cardiovascular events, and mortality.33-53  In the setting of DE, 
these are considered avoidable and unnecessary respiratory pharmacotherapy use in 
minorities and the underserved that are already disproportionately affected by 
cardiovascular disease54-56 increases the risk of poorer outcomes.  There is also DE in 
the diagnosis of asthma versus COPD, as these are both clinically distinct respiratory 
disorders with nuances in treatment recommendations.  It is reported that African-
Americans are considered to have increasing COPD mortality and are 
disproportionately affected by asthma death rates.57-60  However, as spirometry is not 
routinely performed and DE is prevalent in asthma and COPD, a component of these 
poor outcomes may be attributable to missed or delayed diagnoses of other chronic 
conditions or misdiagnosis within asthma and COPD. 
Barriers to the use of spirometry in primary care exist at provider and health 
systems levels.  Previous studies show that primary care providers (PCPs) lack 
knowledge in existing guidelines and in implementing spirometry into primary care 
clinics.11,18,61-64 Beyond these barriers, PCPs struggle with logistical challenges such as 
time and workflow constraints with clinic visits lasting 15 minutes or less in patients with 
multiple chronic medical conditions.62,65 These predisposing and enabling factors 
explain why prior studies that included interventions to educate PCPs and incorporate 
spirometry by training personnel in primary care clinics have had limited results.32,63,66-68  
A new paradigm to improve guideline based care for asthma and COPD which 
includes spirometry is needed and can lead to a better understanding of DE and 
improved patient safety and patient-centered outcomes.  Health Promoters or 
Community health workers (CHWs) have been supplementing medical care by 
disseminating appropriate health care practices for underserved minority populations.  
However, studies which include diagnostic evaluations with spirometry for asthma and 
COPD have not been performed.   The REDEFINE program (Reducing Diagnostic Error 
to Improve PatieNt SafEty in COPD and Asthma) will incorporate health promoters 
working collaboratively with PCPs to address identified barriers to guideline based care 
which includes spirometry for the diagnosis of asthma and COPD for patients at risk for 
DE.  We propose a comparative effectiveness study to better understand the 
epidemiology of DE and to evaluate the effectiveness and economic impact of providing 
the REDEFINE program to an underserved, predominantly minority population with a 
diagnosis of asthma and/or COPD at risk for DE. 
  
 
RESEARCH DESIGN AND METHODS 
 
1. RESEARCH DESIGN  
 
This will be a cluster-randomized comparative effectiveness trial conducted of patients 
with a primary care provider (PCP) diagnosis of COPD and/or asthma seen in outpatient 
primary care provider clinics (i.e. Family Medicine, Miles Square Health Center, and 
Academic Internal Medicine) as well as the CRC (Clinical Research Center) at the 
University of Illinois Hospital and General Internal Medicine  and Famly Medicine Clinics 

Page 3 of 13 
 
at Cook County Health and Hospitals Systems (CCHHS).   Providers will be randomized 
and their patients who fulfill the inclusion criteria will receive the intervention or be in the 
usual care group.  Adults with a clinician-diagnosed COPD and/or asthma at high risk 
for diagnostic error due to lack of spirometry will undergo the REDEFINE intervention or 
usual care based on the PCP randomization .  Outcomes will be assessed every 3 
months for up to one year. 
 
 
2. ELIGIBILITY CRITERIA 
 
A.  Primary care provider (PCP) eligibility criteria: 
Primary care providers (PCPs) will include physicians and nurse practitioners.  PCPs 
specializing in internal medicine or family medicine with at least one half day per week 
outpatient clinic session at the following clinics will be eligible for the study: 
• UI Health:  Family  Medicine (FM) clinics, Academic Internal Medicine (AIM) 
clinics 
• Miles Square Health Center (MSHC) 
• Clinical Research Center (CRC) at UIC 
• Cook County Health and Hospitals Systems (CCHHS):  General Internal 
Medicine (GIM) and Family Medicine 
 
B.  Patient eligibility criteria: 
 
Inclusion criteria: 
1. Age ≥40 years of age 
2. Use of a maintenance respiratory medication and one of the following in the past 
year: 
a. diagnosis of asthma  
b. diagnosis of COPD, emphysema, or chronic bronchitis  
3. No spirometry test performed in the past 3 years 
4. Past or current smoker 
  
Exclusion criteria: 
• Unable to perform adequate spirometry 
• Non-English speaking 
• Pregnancy  
• Plans to move from the Chicago area within the next year 
• Seen by pulmonary or allergy specialist in the past 3 years 
• Any terminal illness with a life expectancy of <6 months  
• Life threatening (e.g. Intensive care admission and/or use of mechanical 
ventilation ) respiratory failure event in the past year  
 
 
3. SUBJECT SELECTION, RECRUITMENT, AND INFORMED CONSENT 
 
PCP Selection, Recruitment, and Informed consent 
 
Primary care providers (PCPs) specializing in internal medicine or family medicine with 
at least one half day per week outpatient clinic will be included in the study.  We 

Page 4 of 13 
 
estimate a total maximum recruitment of 80 eligible PCPs from all sites (approximately 
50 PCPs from UI Health and MSHC sites and approximately 30 PCPs from CCHHS).  
The recruitment will include a combination of paper letter and email invitations with 
endorsement from the clinic directors and other supervisors. A list of eligible PCPs will 
be obtained from each site from the clinic directors.  A research introduction letter will 
be mailed to the qualifying practitioners as well as an email invitation sent to their email 
accounts.  The letter and email will be sent simultaneously to ensure contact and will 
include a short introduction to why the research is being performed and a description of 
participants’ roles in the study.  Also included will be a contact number for those who 
would like to volunteer or who would like additional information.  The letter will include a 
statement that there will be no penalty for not participating.  The letter will also contain a 
postcard with a stamp, where the eligible PCP checks to agree to participate or decline 
to participate. The email will instruct them to reply by email to the same choices.  If a 
response is not received in 2 weeks, a second recruitment letter and email will be sent 
followed by a postcard 2 weeks later. Once a PCP agrees to participate, informed 
consent will be obtained prior to initiation of any study procedures. 
 
Patient Selection, Recruitment, and Informed consent 
 
Approximately 500 patients will be recruited for this study from the FM, AIM, MSHC and 
GIM sites (A total of 250 from UI Health and MSHC sites and a total of 250 from 
CCHHS site).  All sites use the same electronic medical record (EMR) system which is 
Cerner Powerchart.  An Information Systems Specialists (ISS) from UI Health (including 
MSHC) and CCHHS will search the administrative data of their respective sites to 
provide a list of patients meeting the first three of the inclusion criteria listed above and 
are scheduled to be seen in PCP clinics or the CRC (Clinical Research Center at UIC),  
two weeks in the future.  More specifically, using electronic health records, within the 
past 12 months, the following patients will initially be identified:  age ≥ 40 years and 
using at least one maintenance respiratory medication (e.g. long acting beta agonists 
(LABA), long acting anticholinergics (LAA),inhaled corticosteroids (ICS), 
phosphodiesterase-4 inhibitors (PDE-4i), and at least one of the following 1) diagnosis 
of asthma (ICD-9 493.xx or ICD 10 J45.xx), 2) diagnosis of COPD, emphysema, or 
chronic bronchitis (ICD-9 491.xx, 492.xx, 496 or ICD 10 J41.xx, J42.xx, J43.xx, J44.xx). 
.In addition, our ISS will also only include those who have not had a current procedural 
testing (CPT) codes for spirometry (CPT codes:  94010, 94014, 94015, 94016, 94060, 
94070, 94620) or completed order for spirometry testing in the past 3 years.  
 
Medical charts of patients will be reviewed to prescreen for eligibility for the study.  
Participants who meet preliminary eligibility criteria will be mailed a patient recruitment 
letter informing them of the study and our intent to contact them by telephone to 
complete a phone screen approximately one week before the participants’ scheduled 
primary care visit.  The letter will be sent 2 weeks before the planned phone screen and 
will have a phone number to call to opt out of the study.  A patient phone screen is 
conducted to confirm eligibility criteria and the participants’ verbal consent to participate 
in the study is obtained. During the call, we will confirm their scheduled appointment 
date, go over the study, answer any questions, and if the subject agrees, conduct the 
phone screen to verify eligibility criteria.  If eligible, they will be asked to participate in 
the study and if agreeable will be asked to come in 90 minutes before the clinic visit.  
Once a subject agrees to participate, informed consent will be obtained prior to initiation 
of any study procedures.  

Page 5 of 13 
 
 
 
4.  DESCRIPTION OF PROCEDURES 
 
A) PCP Education and Randomization:  
After obtaining PCP informed consent and prior to patient recruitment, a one hour 
educational session will be held for PCPs participating in the study. The purpose 
of this session is to provide education to PCPs about COPD, asthma, spirometry, 
and GOLD and GINA guidelines (GOLD=Global Initiative for Chronic Obstructive 
Lung Disease, GINA=Global Initiative for Asthma). The educational session will 
provide continuing medical education credit to those who attend.  The learning 
objectives will be the following: 1) Review COPD and asthma disease definition, 
presentation, diagnosis and testing including spirometry, 2) be familiar with the 
GOLD and GINA guidelines and recommendations for therapy.   
 
PCPs who consented to participate in the study and completed the education 
session will be randomized to have their patients who meet the study criteria 
receive the intervention or usual care. 
     
B) Patient subject- Intervention:   
On the day of the outpatient visit, subjects will be advised to arrive 90 minutes 
prior to their clinic visit in the same building as the clinic site or the CRC (Clinical 
Research Center at UIC).  The following information will be collected and 
procedures will be performed: 
 
1. Subject demographic and contact information 
2. Co-morbid conditions 
3. Smoking history 
4. Medication history from patient and also from pharmacy used by subjects 
5. A respiratory exacerbation history in the past year  
6. Modified Medical Research Counsel (mMRC) dyspnea scale and  COPD 
Assessment Test 
7. Quality of life measures 
8. Pre and post-bronchodilator (BD) spirometry 
9. De-Escalation Spirometry Screener for patients de-escalating based on 
spirometry (See Based on spirometry findings) 
10. De-Escalation Phone Script  
 
Based on spirometry findings: 
1. If the spirometry findings are consistent with COPD and/or asthma, the 
following will be provided to the provider and patient to have available during 
the clinic visit:  a letter summarizing the interpretation of the findings using 
GOLD/GINA criteria with recommendations for initial guideline driven therapy 
based on GOLD/GINA guidelines.  Subjects will be managed by their PCP 
thereafter. 
2. If the spirometry findings are normal, with approval from the PCP, will de-
escalate respiratory medication therapy via a stepwise process and schedule 
patient back for a repeat pre and post bronchodilator spirometry within 1-2 
weeks at the same time and place as the PCP clinic session or the CRC 
(Clinical Research Center at UIC).  Again with the PCP approval, this 

Page 6 of 13 
 
deescalation and repeat spiromety can occur in 1-2 week intervals until all 
maintenance medications are discontinued as long as the pre and post 
spirometry continues to be normal. After each visit, the following will be 
provided to the provider and patient:  a letter summarizing the interpretation of 
the findings using GOLD/GINA criteria with recommendations for initial 
guideline driven therapy based on GOLD/GINA guidelines, if appropriate.  
Subjects will be managed by their PCP thereafter.    
3. All spirometry test results and the subject’s assessment at the time of the test 
will be uploaded into the subject’s electronic health record for future reference. 
 
 
C) Patient subject- Usual Care:  
On the day of the outpatient visit, subjects will be advised to arrive 60 minutes 
prior to their clinic visit in the same building as the clinic site or the CRC (Clinical 
Research Center).  The following will be performed.  
 
1. Subject demographic and contact information 
2. Co-morbid conditions 
3. Smoking history 
4. Medication history from patient and also from pharmacy used by subjects 
5. A respiratory exacerbation history in the past year  
6. Modified Medical Research Counsel (mMRC) dyspnea scale and COPD 
assessment test 
7. Quality of life measures 
 
Subjects will be advised to go to their clinics and be managed by their PCP 
thereafter. 
 
At the end of the 1 year followup, the patient will be scheduled for a pre and post 
BD spirometry and undergo the same spirometry protocol  (de-escalation 
protocol) as the intervention group. 
Based on spirometry findings: 
1. If the spirometry findings are consistent with COPD and/or asthma, the 
following will be provided to the provider and patient:  a letter summarizing the 
interpretation of the findings using GOLD/GINA criteria with recommendations 
for initial guideline driven therapy based on GOLD/GINA guidelines.  Subjects 
will be managed by their PCP thereafter. 
2. If the spirometry findings are normal, with approval from the PCP, will de-
escalate respiratory medication therapy via a stepwise process and schedule 
patient back for a repeat pre and post bronchodilator spirometry within 1-2 
weeks at the same time and place as the PCP clinic session.  Again with the 
PCP approval, this deescalation and repeat spiromety can occur in 1-2 week 
intervals until all maintenance medications are discontinued as long as the pre 
and post spirometry continues to be normal. After each visit, the following will 
be provided to the provider and patient:  a letter summarizing the interpretation 
of the findings using GOLD/GINA criteria with recommendations for initial 
guideline driven therapy based on GOLD/GINA guidelines, if appropriate.  
Subjects will be managed by their PCP thereafter.   
3. All spirometry test results and the subject’s assessment at the time of the test 
will be uploaded into the subject’s electronic health record for future reference. 

Page 7 of 13 
 
   
D) Outcome Measures:  
1. Primary outcome:   
(i) Accurate classification of patient as having COPD and/or asthma 
(ii) All-cause and respiratory related, acute care outpatient visits, ED visits, 
and hospitalizations 
2. Secondary outcome:  
(i) Appropriate use of respiratory medications based on guidelines 
(ii) Use of other diagnostic testing:  ECG, echocardiograms, CT/CXR, stress 
testing, cardiac catheterization, other pulmonary function tests 
(iii)Initiation of guideline based therapy 
(iv)Quality of life measures 
 
E)  Data collection and follow-up 
1) Baseline data collection obtained at visit zero (V0), in addition to those listed 
under intervention and usual care: 
1. Demographic data (gender, age, self-reported race) 
2. SES related measures:  median household income 
3. Level of education 
4. Type of health insurance or self-pay 
5. Up to two emergency contacts information 
6. List of current respiratory medications from subject’s pharmacy and 
verification with patient 
7. Co-morbidities 
8. History of prior ED visits or hospitalizations in the past one year with 
associated cause  
9.  EQ-5D 5L +B Bolt-on 
10.  SF-36 short form 
11.  Social support survey 
 
2) All subjects will have their medical charts reviewed every 3 months after the 
initial visit (MR1, MR2, MR3, MR4) up to one year.  These electronic medical 
chart reviews will be used to obtain follow-up data since last study contact. 
1. Change in type of health insurance or self-pay 
2. List of current respiratory medications from subject’s pharmacy and 
verification with patient 
3. Use of diagnostic testing:  ECG, echocardiograms, CT/CXR, stress 
testing, cardiac catheterization, other pulmonary function tests 
4. Any ED visits or hospitalizations or acute outpatient care visit and 
associated cause. 
5. Healthcare utilization outside of U of I system (e.g. testing such as 
spirometry, ED and hospitalizations) if available through scanned records 
 
3) All subjects will be contacted every 3 months after the initial visit via 
telephone (T1, T2, T3, T4) up to one year; or they will be given the option to 
complete in person based on subject’s convenience, for example they have a 
doctor appointment near time of study follow-up.  These phone calls will be 
used to obtain follow-up data since last study contact. A reminder post-card 
will be mailed to the subjects a month before the next telephone contact. 
1. Change in type of health insurance or self-pay 

Page 8 of 13 
 
2. List of current respiratory medications from subject’s pharmacy and 
verification with patient 
3. Use of diagnostic testing:  ECG, echocardiograms, CT/CXR, stress 
testing, cardiac catheterization, other pulmonary function tests 
4. Any ED visits or hospitalizations or acute outpatient care visit and 
associated cause. 
5. Healthcare utilization outside of U of I system (e.g. testing such as 
ancillary testing, ED and hospitalizations)  
6. mMRC 
7. A respiratory exacerbation history  
8. EQ-5D 5L +B Bolt-on 
9. SF-36 short form (at 3, 6 and 12 months) 
10. Social support survey (at 6 months and 12 months) 
 
F) Monetary compensation of subjects  
1. PCP compensation: 
UI Health and MSHC PCPs will receive $95 in cash after completion of the 
education session. For CCHHS PCPs, the Division  or Department with receive a 
total of $95 per participant to be part of the divisional fund to be used by the PCP 
at their discretion as allowed by their institution.   
 
2. Patient subject compensation: 
Baseline visit (Vo):  
Same for Intervention and usual care groups:   Subjects will be provided 
$75 in cash for completing the initial study visit.   
Telephone contact (T1-T3):  
Same for Intervention and usual care groups.  Subjects who choose to 
complete the follow-up in person or via telephone will receive $20 in cash 
at the time of the visit or at a later specified time that is convenient for the 
subject. 
Final contact (T4):  
Intervention:   Subjects will receive $95 in cash at the time of the their last 
visit in-person. 
Usual Care Group:   Subjects will receive $95 in cash  at the completion of 
the 1 year spirometry and follow-up. 
Additional spirometry visits after de-escalation of therapy: 
Same for Intervention and usual care groups (except the intervention 
group will receive this near the beginning of the study and usual care 
group will receive this near the end of the study):   Subjects will be 
provided a $50 in cash for each additional spirometry visit.   
 
2.A. Provision to compensation:  If human subject receives over $200.00 
within one (1) calendar year, it is incumbent for the study staff to obtain the 
subjects social security number based on the OBFS guidelines.  However, if 
human subject receives a total under $200.00 within the calendar there is no 
need to obtain social security number from the human subject. 
 
5. STATISTICAL ANALYSES 
All data will be stored in a secure, locked location. Data will be entered and managed 
through the Research Electronic Data Capture (REDCap). REDCap is a secure web-
based application for building and managing online databases.  REDCap is provided by 

Page 9 of 13 
 
the CCTS Design Analysis Core.  Data will be analyzed for clinical effectiveness using 
intention-to-treat principles.69-71 For Aim 1, we will evaluate the misdiagnosis rates of 
the intervened and usual care groups separately at the first visit. Then compare rates 
between groups by using a generalized linear mixed model for binary outcome with two 
cluster levels, PCP and hospital, to account for the dependence within clusters. For the 
Aim 2, to investigate the impact of the misdiagnosis over time (4 time points: 0, 3, 6, 9, 
12 months) on the quality of life and healthcare utilization, we will fit generalized linear 
mixed models with time, group, and their interaction as the main predictors.  Two cluster 
levels, PCP and hospital, will be specified in the model to account for the dependence 
within clusters72,73 and an appropriate link function will be used for each outcome. 
Clinical important confounders will also be adjusted in the models. Before these 
analyses we will use descriptive statistics to describe the sample, and any assumption 
behind each statistical method will be examined during the analysis. A two-sided p-
value less than 0.05 would be considered as statistical significance. All the analyses will 
be conducted by using SAS 9.2 (SAS Inst., Cary, NC). 
 
For Aim 3: Costs:  The intervention costs for the study include the cost of the 
spirometry test, the time of the CHW/health promoter, and time of pulmonologist to 
provide periodic oversight of spirometry validity.  In addition to estimating the costs 
associated with the intervention it will be important to measure the healthcare utilization 
for participants included in the study.  It is possible that the intervention leads to use of 
other healthcare resources, particularly if the patient is determined to be free of 
respiratory disease.  Therefore, we will measure both respiratory-related and overall 
healthcare costs.  To measure these costs, we will determine overall healthcare 
utilization and apply unit costs to each of the events. Using chart reviews, we will 
examine healthcare utilization during the follow-up period.  We will categorize 
healthcare utilization into either respiratory-related or all other healthcare use.  We will 
apply standardized prices to each of the utilization components to estimate the overall 
and respiratory-related healthcare resource use during the study period. The 
standardize prices will be based on either the National Committee for Quality Assurance 
standardize price list for their relative resource use measure or Medicare 
reimbursement rates.  For medications, we will rely on average wholesale price of 
medications to assign an average price to each of the COPD and asthma-related 
medications.  
 Cost-Effectiveness:  The secondary outcome measures included in the study will be 
used to estimate the effectiveness to be used in the cost-utility analysis. We will use 
responses to the EQ5D to estimate patient utility and use that in calculation of quality-
adjusted life-years (QALY).  The area under the curve will be compared between the 
two groups and the difference will be the incremental effect used in the cost-utility 
analysis.  
Cost-utility analyses:  We will evaluate the cost-utility of the intervention compared to 
usual care over the study period using recommended methods for cost-effectiveness 
analysis.74  To compare the cost-effectiveness of the intervention to usual care, the 
findings are summarized into a ratio that provides the results in terms of the costs per 
unit of effect.  We will calculate the difference in intervention costs and respiratory-
related healthcare resource use between groups to determine the numerator of the ratio 
and the denominator will be the difference in QALYs in the cost-utility analysis.  These 
incremental cost-effectiveness ratios (ICERs) will represent the cost per gain in QALYs 
for the intervention compared to standard care.  As part of the cost-utility analysis we 
will evaluate the uncertainty associated with the ICERs.  We will use bootstrapping 

Page 10 of 13 
 
methods to generate confidence limits for the ICERs.75,76  We will display the results 
graphically on a cost-effectiveness plane and generate cost-effectiveness acceptability 
curves for the intervention compared to usual care.77,78  Cost-effectiveness acceptability 
curves display the probability of the intervention being cost-effective given various 
threshold values.78 Thus decision-makers can identify a threshold value appropriate for 
their setting and determine the probability that the intervention will be cost-effective.  We 
will also conduct sensitivity analyses that use the measure of overall healthcare 
utilization in calculation of the costs, as there may not be perfect specificity in identifying 
respiratory-related costs during the follow-up assessments and the intervention may 
lead to differences in non-respiratory costs. 
 
6. SAFETY MONITORING AND ASSESSMENT 
 
Risks of intervention study 
Spirometry is a breathing test commonly utilized in the outpatient primary care setting.  
Risks and discomforts associated with spirometry are possible. The risks include 
shortness of breath and on rare occasion, the subject might experience dizziness, 
cough, or light-headedness. A medication that can open subjects’ airways may be used 
during spirometry testing. This medication, albuterol, is in a class of medications (i.e. 
short acting beta agonist) that is often used to treat subjects suspected with COPD 
and/or asthma as part of usual care. Albuterol may sometimes cause tremors/shaking, 
nervousness, dizziness, difficulty sleeping, headache, irregular heartbeats, drying or 
irritation of mouth, sore throat, upset stomach, and coughing. These effects usually 
disappear within a short time and do not require treatment.  
 
Data Safety Monitoring Plan 
The PI will review monthly data reports reviewing recruitment, consent, intervention 
activities, adverse events, and follow-up.  Although few, if any, intervention-related 
adverse events are anticipated in this study, the study population is at risk for poor 
outcomes, including life-threatening exacerbations and death not caused by the study 
itself.  The PI will comply with prompt reporting of any adverse event to the IRB  
 
 
7. DATA MANAGEMENT 
 
Confidentiality 
To help ensure that patients’ health information remains private, we will restrict access 
to data collected for our study to study personnel only (via use of password-protection 
and locked cabinets for study documents).  Study ID numbers will be generated and will 
be used when discussing and/or reviewing data at study meetings.  Also, study reports 
will report results in aggregate and not contain information that can be used to identify 
individual patients. 
 
Storage of Data 
Data will be collected from participants in the form of questionnaires and will be 
documented in the secure, password protected, web-based Research Electronic Data 
Capture (REDCap) database available only to members of the research team.  The 
research data will be stored securely using subject ID numbers and kept for 6 years 
after the end of the study.    
 

Page 11 of 13 
 
UI Health electronic medical records(EMR) (inpatient and outpatient) will be reviewed by 
staff from UI Health and CCHHS EMR (inpatient and outpatient) will be reviewed by 
staff from CCHHS . Data collected from both institutions will be input into REDCap.  The 
crosswalk file with direct identifiers to the coded data will be created, encrypted, and 
kept on Dr. Joo’s office computer at 840 S. Wood St. Chicago, Il and stored such that 
only authorized inviduals will have access to patient identifying information.  Hardcopies 
of the data will not be made. 
 
 
REFERENCES 
 
1 National Center for Health Statistics. Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and Over in 
the United States, 1998-2009, 2011 
2 Centers for Disease C, Prevention. Vital signs: asthma prevalence, disease characteristics, and self-management 
education: United States, 2001--2009. MMWR Morb Mortal Wkly Rep 2011; 60:547-552. 
3 In: Balogh EP, Miller BT, Ball JR, eds. Improving Diagnosis in Health Care. Washington (DC), 2015 
4 Ball JR, Balogh E. Improving Diagnosis in Health Care: Highlights of a Report From the National Academies of 
Sciences, Engineering, and Medicine. Ann Intern Med 2016; 164:59-61. 
5 Singh H, Graber ML. Improving Diagnosis in Health Care--The Next Imperative for Patient Safety. N Engl J Med 
2015; 373:2493-2495. 
6 Khullar D, Jha AK, Jena AB. Reducing Diagnostic Errors--Why Now? N Engl J Med 2015; 373:2491-2493. 
7 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and 
prevention of chronic obstructive pulmonary disease: World Health Organization and National Heart, 
Lung, and Blood Institute, 2016 
8 Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, MD, USA: 
GINA, 2015 
9 Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary 
disease: a clinical practice guideline update from the American College of Physicians, American College of 
Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 
155:179-191. 
10 National Asthma E, Prevention P. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management 
of Asthma-Summary Report 2007. The Journal of allergy and clinical immunology 2007; 120:S94-138. 
11 Bolton CE, Ionescu AA, Edwards PH, et al. Attaining a correct diagnosis of COPD in general practice. Respir 
Med 2005; 99:493-500. 
12 Damarla M, Celli BR, Mullerova HX, et al. Discrepancy in the use of confirmatory tests in patients hospitalized 
with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 2006; 
51:1120-1124. 
13 Han MK, Kim MG, Mardon R, et al. Spirometry Utilization for COPD: How Do We Measure Up? Chest 2007; 
132:403-409. 
14 Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006; 
129:1509-1515. 
15 Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. 
Chest 2000; 117:346S-353S. 
16 Miravitlles M, de la Roza C, Naberan K, et al. Use of spirometry and patterns of prescribing in COPD in primary 
care. Respir Med 2007; 101:1753-1760. 
17 Mularski RA, Asch SM, Shrank WH, et al. The quality of obstructive lung disease care for adults in the United 
States as measured by adherence to recommended processes. Chest 2006; 130:1844-1850. 
18 Walters JA, Hansen E, Mudge P, et al. Barriers to the use of spirometry in general practice. Aust Fam Physician 
2005; 34:201-203. 
19 O’Dowd LC, Fife D, Tenhave T, et al. Attitudes of physicians toward objective measures of airway function in 
asthma. Am J Med 2003; 114:391-396. 
20 Ghattas C, Dai A, Gemmel DJ, et al. Over diagnosis of chronic obstructive pulmonary disease in an underserved 
patient population. Int J Chron Obstruct Pulmon Dis 2013; 8:545-549. 
21 Prieto-Centurion V, Rolle AJ, Au DH, et al. Multi-center Study Comparing Case Definitions Used to Identify 
Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2014 
22 Han MK, Postma D, Mannino DM, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am 
J Respir Crit Care Med 2007; 176:1179-1184. 
23 Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001; 119:1691-1695. 

Page 12 of 13 
 
24 Franks P, Clancy CM, Naumburg EH. Sex, access, and excess. Ann Intern Med 1995; 123:548-550. 
25 Ohar J, Fromer L, Donohue JF. Reconsidering sex-based stereotypes of COPD. Prim Care Respir J 2011; 20:370-
378. 
26 Tinkelman DG, Price DB, Nordyke RJ, et al. Misdiagnosis of COPD and asthma in primary care patients 40 
years of age and over. J Asthma 2006; 43:75-80. 
27 Abramson MJ, Schattner RL, Sulaiman ND, et al. Accuracy of asthma and COPD diagnosis in Australian general 
practice: a mixed methods study. Prim Care Respir J 2012; 21:167-173. 
28 Melbye H, Drivenes E, Dalbak LG, et al. Asthma, chronic obstructive pulmonary disease, or both? Diagnostic 
labeling and spirometry in primary care patients aged 40 years or more. Int J Chron Obstruct Pulmon Dis 
2011; 6:597-603. 
29 Griffiths C, Feder G, Wedzicha J, et al. Feasibility of spirometry and reversibility testing for the identification of 
patients with chronic obstructive pulmonary disease on asthma registers in general practice. Respir Med 
1999; 93:903-908. 
30 Sichletidis L, Chloros D, Spyratos D, et al. The validity of the diagnosis of chronic obstructive pulmonary 
disease in general practice. Prim Care Respir J 2007; 16:82-88. 
31 Walters JA, Walters EH, Nelson M, et al. Factors associated with misdiagnosis of COPD in primary care. Prim 
Care Respir J 2011; 20:396-402. 
32 Buffels J, Degryse J, Liistro G, et al. Differential diagnosis in a primary care population with presumed airway 
obstruction: a real-life study. Respiration 2012; 84:44-54. 
33 Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of 
usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26. 
34 Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of 
usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26. 
35 Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic 
obstructive pulmonary disease. Ann Intern Med 2008; 149:380-390. 
36 Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in 
patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama 2008; 
300:1439-1450. 
37 Van den Bruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD 
patients: results of a meta-analysis. BMC Pulm Med 2010; 10:50. 
38 Ogale SS, Lee TA, Au DH, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest 
2010; 137:13-19. 
39 Macie C, Wooldrage K, Manfreda J, et al. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J 
Chron Obstruct Pulmon Dis 2008; 3:163-169. 
40 Ringbaek T, Viskum K. Is there any association between inhaled ipratropium and mortality in patients with 
COPD and asthma? Respir Med 2003; 97:264-272. 
41 Guite HF, Dundas R, Burney PG. Risk factors for death from asthma, chronic obstructive pulmonary disease, and 
cardiovascular disease after a hospital admission for asthma. Thorax 1999; 54:301-307. 
42 Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic 
obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. Bmj 
2011; 342:d3215. 
43 Martin-Merino E, Garcia-Rodriguez LA, Masso-Gonzalez EL, et al. Do oral antimuscarinic drugs carry an 
increased risk of acute urinary retention? J Urol 2009; 182:1442-1448. 
44 Armitage JN, Sibanda N, Cathcart PJ, et al. Mortality in men admitted to hospital with acute urinary retention: 
database analysis. Bmj 2007; 335:1199-1202. 
45 Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic 
obstructive pulmonary disease. N Engl J Med 2007; 356:775-789. 
46 Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and 
the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162-166. 
47 Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on 
exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144-
149. 
48 Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol 
(50 microg) on COPD exacerbations. Respir Med 2008; 102:1099-1108. 
49 Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease 
exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 
2008; 177:19-26. 
50 Joo MJ, Au DH, Fitzgibbon ML, et al. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. 
Respir Med 2010; 104:246-252. 

Page 13 of 13 
 
51 Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease 
and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013; 
8:295-304. 
52 McKeever T, Harrison TW, Hubbard R, et al. Inhaled corticosteroids and the risk of pneumonia in people with 
asthma: a case-control study. Chest 2013; 144:1788-1794. 
53 Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med 2004; 169:855-859. 
54 Mensah GA, Mokdad AH, Ford ES, et al. State of disparities in cardiovascular health in the United States. 
Circulation 2005; 111:1233-1241. 
55 Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other 
cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease 
prevention. Circulation 2000; 102:3137-3147. 
56 Ski CF, King-Shier KM, Thompson DR. Gender, socioeconomic and ethnic/racial disparities in cardiovascular 
disease: a time for change. Int J Cardiol 2014; 170:255-257. 
57 Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the 
United States, 2001-2010. NCHS Data Brief 2012:1-8. 
58 Morbidity & Mortality:  2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. In: National Heart Lung 
and Blood Institute, ed, 2012 
59 Dransfield MT, Bailey WC. COPD: racial disparities in susceptibility, treatment, and outcomes. Clin Chest Med 
2006; 27:463-471, vii. 
60 Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 
1998-2009. NCHS Data Brief 2011:1-8. 
61 Barr RG, Celli BR, Martinez FJ, et al. Physician and patient perceptions in COPD: the COPD Resource Network 
Needs Assessment Survey. Am J Med 2005; 118:1415. 
62 Caramori G, Bettoncelli G, Tosatto R, et al. Underuse of spirometry by general practitioners for the diagnosis of 
COPD in Italy. Monaldi Arch Chest Dis 2005; 63:6-12. 
63 Kaminsky DA, Marcy TW, Bachand M, et al. Knowledge and use of office spirometry for the detection of 
chronic obstructive pulmonary disease by primary care physicians. Respir Care 2005; 50:1639-1648. 
64 Foster JA, Yawn BP, Maziar A, et al. Enhancing COPD management in primary care settings. MedGenMed 
2007; 9:24. 
65 Stange KC, Zyzanski SJ, Jaen CR, et al. Illuminating the 'black box'. A description of 4454 patient visits to 138 
family physicians. J Fam Pract 1998; 46:377-389. 
66 Lusuardi M, De Benedetto F, Paggiaro P, et al. A Randomized Controlled Trial on Office Spirometry in Asthma 
and COPD in Standard General Practice *. Chest 2006; 129:844-852. 
67 Walters JA, Hansen EC, Johns DP, et al. A mixed methods study to compare models of spirometry delivery in 
primary care for patients at risk of Chronic Obstructive Pulmonary Disease. Thorax 2007 
68 Walker PP, Mitchell P, Diamantea F, et al. Effect of primary-care spirometry on the diagnosis and management 
of COPD. Eur Respir J 2006; 28:945-952. 
69 Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996; 52:1324-1333. 
70 Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled 
trials. Bmj 1999; 319:670-674. 
71 Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000; 21:167-189. 
72 Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. London, England: 
Oxford University Press, 2000;  
73 Brown H, Prescott R. Applied mixed models in medicine.: John Wiley & Sons, 2006;  
74 Gold M. Cost-Effectiveness in Health and Medicine. New York, New York: Oxford University Press, 1996;  
75 Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-
parametric approach to confidence interval estimation. Health Econ 1997; 6:327-340. 
76 Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993;  
77 Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 
1998; 7:723-740. 
78 van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 
3:309-319.